EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access

Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy

Saaz Mantri, An-Chiao Cheng, Kelley Saia, Hira Shrestha, Rachel Amgott, Jonathan Bressler, Martha M Werler, Ginny Carter, Hendree E Jones, Elisha M Wachman

Early Human Development · 2024

DOI: 10.1016/j.earlhumdev.2024.106051 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Early Human Development, 2024. Verfasst von Saaz Mantri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, United States of America. Electronic address: saazym@…. Hauptthemen laut MEDLINE: Naltrexone, Narcotic Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Naltrexone is a medication used to treat both opioid and alcohol use disorder with limited experience in pregnant individuals, particularly in comparison to more commonly utilized treatments such as buprenorphine-naloxone. The long-term outcomes of infants exposed to naltrexone has not been previously examined. AIMS: To compare the neurobehavioral outcomes of naltrexone versus buprenorphine-naloxone exposed infants. STUDY DESIGN: Multi-centered prospective cohort study. SUBJECTS: Pregnant people on prescribed buprenorphine-naloxone or naltrexone were enrolled during pregnancy and the dyad followed until 12 months after delivery. OUTCOME MEASURES: Infants were evaluated at 4-6 weeks corrected gestational age (CGA) using the NICU Neonatal Neurobehavioral Scale (NNNS) and at the 12-month CGA visit using the Ages and Stages Questionnaire, Third Edition (ASQ-3). RESULTS: There were 7 dyads in the naltrexone group and 34 in the buprenorphine-naloxone group. On the NNNS, infants exposed to naltrexone had higher median scores for arousal and excitability, and lower median scores for attention and regulation at 4-6 weeks CGA compared to the buprenorphine-naloxone group. None of the infants in the naltrexone group were monitored for NOWS and had shorter length of hospital stay compared with the buprenorphine-naloxone group. Although no statistically significant differences were observed, more infants in the buprenorphine-naloxone group were identified as at risk for development delays in the communication, problem solving, and personal social domains of the ASQ-3 at 12 months CGA. Results should be interpreted with caution given this study's small sample size and lack of a prospective comparison cohort. CONCLUSIONS: In this small cohort, there are differences noted in infant neurobehavior by NNNS at 4-6 weeks of age when comparing the buprenorphine-naloxone and naltrexone groups. At 12 months, ASQ-3 scores were similar but with percentage differences in potential development delay risk observed between the two groups. Larger cohort studies are needed to determine the long-term child outcomes after naltrexone exposure in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneNarcotic AntagonistsHumansFemalePregnancyInfant, NewbornAdultBuprenorphinePrenatal Exposure Delayed EffectsMaleBuprenorphine, Naloxone Drug CombinationChild DevelopmentInfantInfant BehaviorProspective StudiesOpioid-Related DisordersNaloxonePregnancy Complications

Stichwörter der Autor:innen

ASQ-3NNNSNaltrexoneNeurobehaviorNeurodevelopmentbuprenorphine-naloxone

Substanzen

NaltrexoneNarcotic AntagonistsBuprenorphineBuprenorphine, Naloxone Drug CombinationNaloxone

Autor:innen und Institutionen

  • Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA, United States of America. Electronic address: saazym@bu.edu.
  • Department of Pediatrics, Boston Medical Center, 670 Albany Street, Boston, MA 02118, United States of America. Electronic address: anchiao.cheng@bmc.org.
  • Department of Obstetrics & Gynecology, Boston Medical Center, One Boston Medical Center Place, Boston, MA 02118, United States of America. Electronic address: Kelley.Saia@bmc.org.
  • Department of Neurology, McCance Center for Brain Health, Massachusetts General Hospital, 399 Revolution Drive, Somerville, MA 02145, United States of America. Electronic address: Hshrestha@mgh.harvard.edu.
  • Department of Pediatrics, Boston Medical Center, 801 Albany Street, Boston, MA 02119, United States of America. Electronic address: Rachel.Amgott@bmc.org.
  • Department of Pediatrics, Boston Medical Center, 801 Albany Street, Boston, MA 02119, United States of America. Electronic address: Jonathan.Bressler@bmc.org.

Förderung

  • NICHD NIH HHS

Zitieren

APA

Mantri, S., Cheng, A. C., Saia, K., Shrestha, H., Amgott, R., Bressler, J., Werler, M. M., Carter, G., Jones, H. E., & Wachman, E. M. (2024). Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Human Development. https://doi.org/10.1016/j.earlhumdev.2024.106051

Vancouver

Mantri S, Cheng AC, Saia K, Shrestha H, Amgott R, Bressler J, et al. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Human Development. 2024. doi:10.1016/j.earlhumdev.2024.106051

BibTeX
@article{Mantri2024,
  author = {Mantri, Saaz and Cheng, An-Chiao and Saia, Kelley and Shrestha, Hira and Amgott, Rachel and Bressler, Jonathan and Werler, Martha M and Carter, Ginny and Jones, Hendree E and Wachman, Elisha M},
  title = {Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy},
  journal = {Early Human Development},
  year = {2024},
  doi = {10.1016/j.earlhumdev.2024.106051}
}
Kostenlos starten →